Zimmer Biomet reports Q4 EPS $1.88, consensus $1.83

Reports Q4 revenue $1.83B, consensus $1.76B. "We closed out the fourth quarter strong, driven by the solid execution of our team and meaningful innovation in our portfolio – all against a backdrop of continued recovery post-pandemic," said Bryan Hanson, chairman, president and CEO of Zimmer Biomet. "As we enter 2023, we expect macro pressures to continue, but also to stabilize, setting up ZB to achieve attractive growth and mark another key milestone in our transformation journey. We remain committed to building out our portfolio, delivering on our mission and creating value for all of our stakeholders."